AI Insight: Amgen's current price implies a near 50% undervaluation relative to the high-confidence fair value of $610.71, supported by robust DCF valuation ($1,012.09 midpoint). Despite strong profitability and efficiency, low leverage and growth scores signal risk in expansion potential. Monte Carlo simulation shows significant upside with limited downside risk (2.9%), indicating high valuation volatility but asymmetric opportunity.